<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers <italic>via</italic> the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Differential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch effectiveness, <italic>in vitro</italic> release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10–0.15 mm), tensile strength (4.62–9.98 MPa) and modulus of elasticity (20–29 MPa). There were no significant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side effects; however, studies of longer duration are required to determine the effectiveness in treating OAB.</p></abstract>

The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment. Patches were prepared using various polymers and plasticizers via the solvent casting method. The patches were characterized for tensile strength, thickness, moisture content, modulus of elasticity and water absorption capacity. Differential scanning calorimetry and Fourier transform infrared analyses were also performed. To determine patch effectiveness, in vitro release, permeation and animal studies were performed. The patches showed satisfactory percentage of release, up to 89.9 %, and their mechanical properties included thickness (0.10–0.15 mm), tensile strength (4.62–9.98 MPa) and modulus of elasticity (20–29 MPa). There were no significant interactions between TT and other excipients. Animal studies indicated that the TT patch reduced the incidence of side effects; however, studies of longer duration are required to determine the effectiveness in treating OAB.

Transdermal delivery of tolterodine tartrate for overactive bladder treatment: <italic>In vitro</italic> and <italic>in vivo</italic> evaluation

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Transdermal delivery of tolterodine tartrate for overactive bladder treatment:  and  evaluation

The purpose of the study was to develop a transdermal tolterodine tartrate (TT) patch and to analyse its efficacy for overactive bladder (OAB) treatment....

Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation

Data publikacji: 30 sie 2017

Zakres stron: 325 - 339

Przyjęty: 11 maj 2017

DOI: https://doi.org/10.1515/acph-2017-0027

Słowa kluczowe
tolterodine tartrate, transdermal, overactive bladder, matrix patches, permeation

© 2017 Rajan Rajabalaya et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Dodatkowe informacje o materiałach

Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation

Data publikacji: 30 sie 2017

Zakres stron: 325 - 339

Przyjęty: 11 maj 2017

DOI: https://doi.org/10.1515/acph-2017-0027

Słowa kluczowetolterodine tartrate, transdermal, overactive bladder, matrix patches, permeation

© 2017 Rajan Rajabalaya et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Dodatkowe informacje o materiałach

Słowa kluczowe
tolterodine tartrate, transdermal, overactive bladder, matrix patches, permeation